New drug trial targets root cause of stubborn blood disorder
NCT ID NCT07190261
Summary
This study is testing an experimental drug called enatumab for adults with a specific type of autoimmune hemolytic anemia (wAIHA) that has come back or not improved after at least two standard treatments. The drug works by guiding the body's own immune T-cells to attack the abnormal plasma cells that produce the harmful antibodies destroying red blood cells. The main goal is to see if this approach can control the disease and reduce hemolysis in patients who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking union medical college hospital
Beijing, Shuangfuyuan, NO I., 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.